Article Figures & Data
Figures
- Figure 1 Flowchart of Case Ascertainment
This flowchart depicts how the 318 ocrelizumab-treated patients with relapsing-remitting multiple sclerosis (RRMS) were identified. The source population was all patients with multiple sclerosis (MS) treated with ocrelizumab in 5 German centers during the period between January 2020 and September 2020. We excluded patients with MS who were treated with ocrelizumab due to a primary progressive disease course (PPMS), if only the 2 induction cycles with 300 mg were administered (treatment duration with ocrelizumab <6 months (Mo) during the observational period). SID and EID do not refer to the first 2 half doses with 300 mg, respectively, if patients experienced an extended interval dosing (EID) before Infusion C (the infusion administered between January 2020 and September 2020 that led to the division of the 2 groups–standard interval dosing [SID] and EID), or if the patient for any other reason did not satisfy the inclusion criteria (e.g., loss of follow-up [LOF]).
- Figure 2 Flowchart of the Study Procedure
1Infusion A was defined as the second last ocrelizumab infusion (300 mg or 600 mg cycles) before January 2020 (before the coronavirus disease 2019 pandemic started in Germany). 2Infusion B was defined as the last ocrelizumab infusion (second 300 mg infusion or 600 mg dose) before January 2020 and as the beginning of the observation interval. 3The infusion that followed on, further referred to as Infusion C, was the infusion administered between January 2020 and September 2020 (always 600 mg maintenance cycle). EID = extended interval dosing; FU = follow-up; SID = standard interval dosing.
- Figure 3 B-Cell Levels Before and During Ocrelizumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis
(A) CD19+ B-cell levels at sampling immediately before ocrelizumab infusions 1 to 5 in the standard interval dosing (SID) group compared with the extended interval dosing (EID) group. Infusion number 1 represents both baseline ocrelizumab infusions (2 × 300 mg with a 2-week interval). The numbers of cases used to estimate the means and SDs are shown below the figure. B-cell counts are presented as mean absolute counts of CD19+ cells/μL of blood. (B) The CD19+ B-cell levels immediately before ocrelizumab Infusion C (the infusion administered between January 2020 and September 2020 that led to the division of the 2 groups—SID and EID). B-cell counts are presented as absolute numbers of CD19+ cells/μL of peripheral blood. The number of patients with absolute CD19+ B-cell counts available at Infusion C is shown below the figure. (C) CD19+ B-cell counts immediately before ocrelizumab Infusion C are depicted. CD19+ B-cell numbers of patients who experienced either a 3-month confirmed progression of disability (CPD, left), a relapse (center), or MRI progression (either new or enlarged T2-weighted lesions or T1-weighted gadolinium enhancement, right) between Infusion B and follow-up are highlighted in red. The number of patients with absolute CD19+ B-cell counts available at Infusion C as well as those with disease activity is shown below the figure.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg